Journal of Neuroimmunology
Volume 239, Issue 1 , Pages 13-20 , 28 October 2011

Role of glial cells in innate immunity and their role in CNS demyelination

Received 12 June 2011 ,Revised 9 August 2011 ,Accepted 16 August 2011.

References 

  1. Akassoglou K, Probert L, Kontogeorgos G, Kollias G. Astrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice. J. Immunol. 1997;158:438–445
  2. Akira S. Toll-like receptor signaling. J. Biol. Chem. 2003;278:38105–38108
  3. Andersen O, Lygner PE, Bergstrom T, Andersson M, Vahlne A. Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J. Neurol. 1993;240:417–422
  4. Andersson PB, Perry VH, Gordon S. Intracerebral injection of proinflammatory cytokines or leukocyte chemotaxins induces minimal myelomonocytic cell recruitment to the parenchyma of the central nervous system. J. Exp. Med. 1992;176:255–259
  5. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol. 2007;61:288–299
  6. Asgari N, Owens T, Frokiaer J, Stenager E, Lillevang ST, Kyvik KO. Neuromyelitis optica (NMO) — an autoimmune disease of the central nervous system (CNS). Acta Neurol. Scand. 2010;240:369–384
  7. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 2004;55:458–468
  8. Bhat R, Steinman L. Innate and adaptive autoimmunity directed to the central nervous system. Neuron. 2009;64:123–132
  9. Bhat NR, Zhang P, Bhat AN. Cytokine induction of inducible nitric oxide synthase in an oligodendrocyte cell line: role of p38 mitogen-activated protein kinase activation. J. Neurochem. 1999;72:472–478
  10. Bielig H, Rompikuntal PK, Mitesh D, Zurek B, Lindmark B, Ramstedt M, et al. NOD-like receptor activation by outer-membrane vesicles (OMVs) from non-O1 non-O139 Vibrio cholerae is modulated by the quorum sensing regulator HapR. Infect. Immun. 2011;79:1418–1427
  11. Bluestone JA, Kuchroo V. Autoimmunity. Curr. Opin. Immunol. 2009;21:579–581
  12. Bo L. The histopathology of grey matter demyelination in multiple sclerosis. Acta Neurol. Scand. Suppl. 2009;51–57
  13. Boullerne AI, Benjamins JA. Nitric oxide synthase expression and nitric oxide toxicity in oligodendrocytes. Antioxid. Redox Signal. 2006;8:967–980
  14. Brown GC, Bal-Price A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol. Neurobiol. 2003;27:325–355
  15. Bruck W. Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis. J. Neurol. 2005;252(Suppl. 5):v10–v15
  16. Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. J. Neuropathol. Exp. Neurol. 2002;61:1013–1021
  17. Bsibsi M, Bajramovic JJ, Van Duijvenvoorden E, Persoon C, Ravid R, Van Noort JM, et al. Identification of soluble CD14 as an endogenous agonist for Toll-like receptor 2 on human astrocytes by genome-scale functional screening of glial cell derived proteins. Glia. 2007;55:473–482
  18. Buljevac D, Flach HZ, Hop WC, Hijdra D, Laman JD, Savelkoul HF, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain. 2002;125:952–960
  19. Campbell IL, Abraham CR, Masliah E, Kemper P, Inglis JD, Oldstone MB, et al. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc. Natl. Acad. Sci. U. S. A. 1993;90:10061–10065
  20. Chakravarty S, Herkenham M. Toll-like receptor 4 on nonhematopoietic cells sustains CNS inflammation during endotoxemia, independent of systemic cytokines. J. Neurosci. 2005;25:1788–1796
  21. Chiang CS, Powell HC, Gold LH, Samimi A, Campbell IL. Macrophage/microglial-mediated primary demyelination and motor disease induced by the central nervous system production of interleukin-3 in transgenic mice. J. Clin. Invest. 1996;97:1512–1524
  22. Colton CA, Gilbert DL. Microglia, an in vivo source of reactive oxygen species in the brain. Adv. Neurol. 1993;59:321–326
  23. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502–1517
  24. Corbin JG, Kelly D, Rath EM, Baerwald KD, Suzuki K, Popko B. Targeted CNS expression of interferon-gamma in transgenic mice leads to hypomyelination, reactive gliosis, and abnormal cerebellar development. Mol. Cell. Neurosci. 1996;7:354–370
  25. Correale J, Farez M. Association between parasite infection and immune responses in multiple sclerosis. Ann. Neurol. 2007;61:97–108
  26. Denis M. Human monocytes/macrophages: NO or no NO?. J. Leukoc. Biol. 1994;55:682–684
  27. Dermietzel R, Hofstadter F. Gap junctions in health and disease. Virchows Arch. 1998;432:177–186
  28. Dermietzel R, Hertberg EL, Kessler JA, Spray DC. Gap junctions between cultured astrocytes: immunocytochemical, molecular, and electrophysiological analysis. J. Neurosci. 1991;11:1421–1432
  29. Draisma A, Dorresteijn M, Pickkers P, van der Hoeven H. The effect of systemic iNOS inhibition during human endotoxemia on the development of tolerance to different TLR-stimuli. Innate Immun. 2008;14:153–159
  30. Du C, Yao SY, Ljunggren-Rose A, Sriram S. Chlamydia pneumoniae infection of the central nervous system worsens experimental allergic encephalitis. J. Exp. Med. 2002;196:1639–1644
  31. Farina C, Krumbholz M, Giese T, Hartmann G, Aloisi F, Meinl E. Preferential expression and function of Toll-like receptor 3 in human astrocytes. J. Neuroimmunol. 2005;159:12–19
  32. Felts PA, Woolston A-M, Fernando HB, Asquith S, Gregson NA, Mizzi OJ, et al. Inflammation and primary demyelination induced by the intraspinal injection of lipopolysaccharide. Brain. 2005;128:1649–1666
  33. Fernandez M, Montalban X, Comabella M. Orchestrating innate immune responses in multiple sclerosis: molecular players. J. Neuroimmunol. 2010;225:5–12
  34. Frohman EM. Multiple sclerosis. Med. Clin. North Am. 2003;87:867–897viii-ix
  35. Frohman EM, Racke MK, Raine CS. Multiple sclerosis — the plaque and its pathogenesis. N. Engl. J. Med. 2006;354:942–955
  36. Graber DJ, Snyder-Keller A, Lawrence DA, Turner JN. Neurodegeneration by activated microglia across a nanofiltration membrane. J. Biochem. Mol. Toxicol. 2011;
  37. Graeber MB. Changing face of microglia. Science. 2011;330:783–788
  38. Graeber MB, Streit WJ. Microglia: biology and pathology. Acta Neuropathol. 2011;119:89–105
  39. Hall SM, Redford EJ, Smith KJ. Tumour necrosis factor-alpha has few morphological effects within the dorsal columns of the spinal cord, in contrast to its effects in the peripheral nervous system. J. Neuroimmunol. 2000;106:130–136
  40. Harry GJ, Kraft AD. Neuroinflammation and microglia: considerations and approaches for neurotoxicity assessment. Expert Opin. Drug Metab. Toxicol. 2008;4:1265–1277
  41. Henderson AP, Barnett MH, Parratt JD, Prineas JW. Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann. Neurol. 2009;66:739–753
  42. Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors: emerging therapeutics?. Nat. Rev. Drug Discov. 2010;9:293–307
  43. Hinson SR, Roemer SF, Lucchinetti CF, Fryer JP, Kryzer TJ, Chamberlain JL, et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J. Exp. Med. 2008;205:2473–2481
  44. Hohlfeld R, Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc. Natl. Acad. Sci. U. S. A. 2004;101(Suppl. 2):14599–14606
  45. Honnorat J. Autoimmune limbic encephalitis: an expanding concept. Lancet Neurol. 2010;9:24–25
  46. Huang Q, Pope RM. Toll-like receptor signaling: a potential link among rheumatoid arthritis, systemic lupus, and atherosclerosis. J. Leukoc. Biol. 2010;88:253–262
  47. Izumo S. Neuropathology of HTLV-1-associated myelopathy (HAM/TSP). Neuropathology; 2010;
  48. Jack C, Ruffini F, Bar-Or A, Antel JP. Microglia and multiple sclerosis. J. Neurosci. Res. 2005;81:363–373
  49. Jack CS, Arbour N, Manusow J, Montgrain V, Blain M, McCrea E, et al. TLR signaling tailors innate immune responses in human microglia and astrocytes. J. Immunol. 2005;175:4320–4330
  50. Jack C, Antel J, Bruck W, Kuhlmann T. Contrasting potential of nitric oxide and peroxynitrite to mediate oligodendrocyte injury in multiple sclerosis. Glia. 2007;55:926–934
  51. Johnson AB. Alexander disease: a leukodystrophy caused by a mutation in GFAP. Neurochem. Res. 2004;29:961–964
  52. Kale N, Pittock SJ, Lennon VA, Thomsen K, Roemer S, McKeon A, et al. Humoral pattern II multiple sclerosis pathology not associated with neuromyelitis Optica IgG. Arch. Neurol. 2009;66:1298–1299
  53. Kantarci OH, Weinshenker BG. Natural history of multiple sclerosis. Neurol. Clin. 2005;23:17–38v.
  54. Kasper LH, Shoemaker J. Multiple sclerosis immunology: the healthy immune system vs the MS immune system. Neurology 74 Suppl. 2010;1:S2–8
  55. Kenny EF, O'Neill LA. Signalling adaptors used by Toll-like receptors: an update. Cytokine. 2008;43:342–349
  56. Kepp O, Galluzzi L, Kroemer G. Mitochondrial control of the NLRP3 inflammasome. Nat. Immunol. 2011;12:199–200
  57. Khan NL, Jeffree MA, Good C, Macleod W, Al-Sarraj S. Histopathology of VGKC antibody-associated limbic encephalitis. Neurology. 2009;72:1703–1705
  58. Kurtzke JF. Epideiologic evidence for MS as an infection. Clin. Microbiol. Rev. 1993;6:382–427
  59. Lacroix S, Feinstein D, Rivest S. The bacterial endotoxin lipopolysaccharide has the ability to target the brain in upregulating its membrane CD14 receptor within specific cellular populations. Brain Pathol. 1998;8:625–640
  60. Lamkanfi M. Emerging inflammasome effector mechanisms. Nat. Rev. Immunol. 2011;11:213–220
  61. Lassmann H, Ransohoff RM. The CD4-Th1 model for multiple sclerosis: a critical [correction of crucial] re-appraisal. Trends Immunol. 2004;25:132–137
  62. Lehnardt S. Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. Glia. 2010;58:253–263
  63. Lehnardt S, Lachance C, Patrizi S, Lefebvre S, Follett PL, Jensen FE, et al. The toll-like receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS. J. Neurosci. 2002;22:2478–2486
  64. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106–2112
  65. Li J, Baud O, Vartanian T, Volpe JJ, Rosenberg PA. Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. Proc. Natl. Acad. Sci. U. S. A. 2005;102:9936–9941
  66. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787–795
  67. Lin W, Harding HP, Ron D, Popko B. Endoplasmic reticulum stress modulates the response of myelinating oligodendrocytes to the immune cytokine interferon-gamma. J. Cell Biol. 2005;169:603–612
  68. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000;47:707–717
  69. Lumsden CE. Neuropathology of Multiple Sclerosis. In:  Koetsler JC editors. Handbook of Clinical Neurology. Vol. 3:Elsevier Science Publishing; 1972;p. 217–309
  70. Magana SM, Pittock SJ, Lennon VA, Keegan BM, Weinshenker BG, Lucchinetti CF. Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease. Arch. Neurol. 2009;66:964–966
  71. Marignier R, Nicolle A, Watrin C, Touret M, Cavagna S, Varrin-Doyer M, et al. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain. 2010;133:2578–2591
  72. Marik C, Felts PA, Bauer J, Lassmann H, Smith KJ. Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity?. Brain. 2007;130:2800–2815
  73. Matsuoka T, Suzuki SO, Iwaki T, Tabira T, Ordinario AT, Kira J. Aquaporin-4 astrocytopathy in Balo's disease. Acta Neuropathol. 2010;120:651–660
  74. Matyszak MK, Perry VH. Demyelination in the central nervous system following a delayed-type hypersensitivity response to bacillus Calmette-Guerin. Neuroscience. 1995;64:967–977
  75. McCormack WJ, Parker AE, O'Neill LA. Toll-like receptors and NOD-like receptors in rheumatic diseases. Arthritis Res. Ther. 2009;11:243
  76. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 2007;8:913–919
  77. McKeon A, Fryer JP, Apiwattanakul M, Lennon VA, Hinson SR, Kryzer TJ, et al. Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch. Neurol. 2009;66:1134–1138
  78. Merrill JE, Murphy SP, Mitrovic B, Mackenzie-Graham A, Dopp JC, Ding M, et al. Inducible nitric oxide synthase and nitric oxide production by oligodendrocytes. J. Neurosci. Res. 1997;48:372–384
  79. Metz I, Lucchinetti CF, Openshaw H, Garcia-Merino A, Lassmann H, Freedman MS, et al. Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain. 2007;130:1254–1262
  80. Minghetti L, Walsh DT, Levi G, Perry VH. In vivo expression of cyclooxygenase-2 in rat brain following intraparenchymal injection of bacterial endotoxin and inflammatory cytokines. J. Neuropathol. Exp. Neurol. 1999;58:1184–1191
  81. Molina-Holgado E, Vela JM, Arevalo-Martin A, Guaza C. LPS/IFN-gamma cytotoxicity in oligodendroglial cells: role of nitric oxide and protection by the anti-inflammatory cytokine IL-10. Eur. J. Neurosci. 2001;13:493–502
  82. Nagy JI, Rash JE. Astrocyte and oligodendrocyte connexins of the glial syncytium in relation to astrocyte anatomical domains and spatial buffering. Cell Commun. Adhes. 2003;10:401–406
  83. Nagy JI, Ionescu AV, Lynn BD, Rash JE. Coupling of astrocyte connexins Cx26, Cx30, Cx43 to oligodendrocyte Cx29, Cx32, Cx47: implications from normal and connexin32 knockout mice. Glia. 2003;44:205–218
  84. Nobuhara Y, Nakahara K, Higuchi I, Yoshida T, Fushiki S, Osame M, et al. Juvenile form of Alexander disease with GFAP mutation and mitochondrial abnormality. Neurology. 2004;63:1302–1304
  85. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N. Engl. J. Med. 2000;343:938–946
  86. O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10years of progress. Immunol. Rev. 2008;226:10–18
  87. O'Neill LA. Primer: Toll-like receptor signaling pathways — what do rheumatologists need to know?. Nat. Clin. Pract. Rheumatol. 2008;4:319–327
  88. O'Neill LA, Bryant CE, Doyle SL. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol. Rev. 2009;61:177–197
  89. Orthmann-Murphy JL, Freidin M, Fischer E, Scherer SS, Abrams CK. Two distinct heterotypic channels mediate gap junction coupling between astrocyte and oligodendrocyte connexins. J. Neurosci. 2007;27:13949–13957
  90. Owens T. Toll-like receptors in neurodegeneration. Curr. Top. Microbiol. Immunol. 2009;336:105–120
  91. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am. J. Physiol. Cell Physiol. 2006;290:C917–C924
  92. Parratt JD, Prineas JW. Neuromyelitis optica: a demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes. Mult. Scler. 2011;16:1156–1172
  93. Pawate S, Sriram S. The role of infections in the pathogenesis and course of multiple sclerosis. Ann. Indian Acad. Neurol. 2011;13:80–86
  94. Perry VH, Andersson PB. The inflammatory response in the CNS. Neuropathol. Appl. Neurobiol. 1992;18:454–459
  95. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 2001;50:389–400
  96. Pifer R, Benson A, Sturge CR, Yarovinsky F. UNC93B1 is essential for TLR11 activation and IL-12-dependent host resistance to Toxoplasma gondii. J. Biol. Chem. 2011;286:3307–3314
  97. Prinz M, Mildner A. Microglia in the CNS: immigrants from another world. Glia. 2011;59:177–187
  98. Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc. Natl. Acad. Sci. U. S. A. 1995;92:11294–11298
  99. Ransohoff RM, Cardona AE. The myeloid cells of the central nervous system parenchyma. Nature. 2010;468:253–262
  100. Rapp NS, Gilroy J, Lerner AM. Role of bacterial infection in exacerbation of multiple sclerosis. Am. J. Phys. Med. Rehabil. 1995;74:415–418
  101. Rejdak K, Eikelenboom MJ, Petzold A, Thompson EJ, Stelmasiak Z, Lazeron RH, et al. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology. 2004;63:1439–1445
  102. Rejdak K, Petzold A, Sharpe MA, Kay AD, Kerr M, Keir G, et al. Cerebrospinal fluid nitrite/nitrate correlated with oxyhemoglobin and outcome in patients with subarachnoid hemorrhage. J. Neurol. Sci. 2004;219:71–76
  103. Rivest S. Regulation of innate immune responses in the brain. Nat. Rev. Immunol. 2009;9:429–439
  104. Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol. 2006;5:343–354
  105. Rubbo H, Trostchansky A, O'Donnell VB. Peroxynitrite-mediated lipid oxidation and nitration: mechanisms and consequences. Arch. Biochem. Biophys. 2009;484:167–172
  106. Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS. Papadopoulos, M.C., Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain. 2010;133:349–361
  107. Scheikl T, Pignolet B, Mars LT, Liblau RS. Transgenic mouse models of multiple sclerosis. Cell. Mol. Life Sci. 2010;67:4011–4034
  108. Schneemann M, Schoeden G. Macrophage biology and immunology: man is not a mouse. J. Leukoc. Biol. 2007;81:579;discussion 580
  109. Schneemann M, Schoedon G, Linscheid P, Walter R, Blau N, Schaffner A. Nitrite generation in interleukin-4-treated human macrophage cultures does not involve the nitric oxide synthase pathway. J. Infect. Dis. 1997;175:130–135
  110. Schnell L, Fearn S, Klassen H, Schwab ME, Perry VH. Acute inflammatory responses to mechanical lesions in the CNS: differences between brain and spinal cord. Eur. J. Neurosci. 1999;11:3648–3658
  111. Schnell L, Fearn S, Schwab ME, Perry VH, Anthony DC. Cytokine-induced acute inflammation in the brain and spinal cord. J. Neuropathol. Exp. Neurol. 1999;58:245–254
  112. Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv. Immunol. 2007;96:41–101
  113. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, et al. Dysregulated Epstein–Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 2007;204:2899–2912
  114. Serres S, Anthony DC, Jiang Y, Broom KA, Campbell SJ, Tyler DJ, et al. Systemic inflammatory response reactivates immune-mediated lesions in rat brain. J. Neurosci. 2009;29:4820–4828
  115. Sharma R, Fischer MT, Bauer J, Felts PA, Smith KJ, Misu T, et al. Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination. Acta Neuropathol. 2010;120:223–236
  116. Shaw PJ, Lamkanfi M, Kanneganti TD. NOD-like receptor (NLR) signaling beyond the inflammasome. Eur. J. Immunol. 2011;40:624–627
  117. Shi Z, Cai Z, Sanchez A, Zhang T, Wen S, Wang J, et al. A novel Toll-like receptor that recognizes vesicular stomatitis virus. J. Biol. Chem. 2011;286:4517–4524
  118. Sloane JA, Batt C, Ma Y, Harris ZM, Trapp B, Vartanian T. Hyaluronan blocks oligodendrocyte progenitor maturation and remyelination through TLR2. Proc. Natl. Acad. Sci. U. S. A. 2010;107:11555–11560
  119. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J. Immunol. 2001;167:2887–2894
  120. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005;23:683–747
  121. Sriram S, Rodriguez M. Indictment of the microglia as the villain in multiple sclerosis. Neurology. 1997;48:464–470
  122. Sriram S, Steiner I. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann. Neurol. 2005;58:939–945
  123. Stadelmann C, Wegner C, Bruck W. Inflammation, demyelination, and degeneration — recent insights from MS pathology. Biochim. Biophys. Acta. 2011;1812(2):275–282
  124. Takeda K, Akira S. Toll-like receptors in innate immunity. Int. Immunol. 2005;17:1–14
  125. Tani M, Fuentes ME, Peterson JW, Trapp BD, Durham SK, Loy JK, et al. Neutrophil infiltration, glial reaction, and neurological disease in transgenic mice expressing the chemokine N51/KC in oligodendrocytes. J. Clin. Invest. 1996;98:529–539
  126. Taupin V, Renno T, Bourbonniere L, Peterson AC, Rodriguez M, Owens T. Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage/microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor-alpha in the central nervous system. Eur. J. Immunol. 1997;27:905–913
  127. Taylor DL, Pirianov G, Holland S, McGinnity CJ, Norman AL, Reali C, et al. Attenuation of proliferation in oligodendrocyte precursor cells by activated microglia. J. Neurosci. Res. 2010;88:1632–1644
  128. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, et al. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J. Exp. Med. 2002;195:99–111
  129. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu. Rev. Neurosci. 2008;31:247–269
  130. van Horssen J, Witte ME, Schreibelt G, de Vries HE. Radical changes in multiple sclerosis pathogenesis. Biochim. Biophys. Acta. 2010;1812:141–150
  131. van Noort JM, Bsibsi M. Toll-like receptors in the CNS: implications for neurodegeneration and repair. Prog. Brain Res. 2009;175:139–148
  132. Vedeler CA, Storstein A. Autoimmune limbic encephalitis. Acta Neurol. Scand. Suppl. 2009;63–67
  133. von Herrath MG, Efrat S, Oldstone MB, Horwitz MS. Expression of adenoviral E3 transgenes in beta cells prevents autoimmune diabetes. Proc. Natl. Acad. Sci. U. S. A. 1997;94:9808–9813
  134. Weiner HL. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J. Neurol. 2008;255(Suppl. 1):3–11
  135. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?. Ann. Neurol. 2009;65:239–248
  136. Weinshenker BG. The natural history of multiple sclerosis: update 1998. Semin. Neurol. 1998;18:301–307
  137. Weinshenker BG, Issa M, Baskerville J. Long-term and short-term outcome of multiple sclerosis: a 3-year follow-up study. Arch. Neurol. 1996;53:353–358
  138. Weinshenker BG, Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA. NMO-IgG: a specific biomarker for neuromyelitis optica. Dis. Markers. 2006;22:197–206
  139. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol. 2010;11:7–13
  140. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805–815
  141. Yao S, Pandey P, Rose A, Sriram S. LPS mediated injury to oligodendrocytes is mediated by the activation of nNOS: relevance to human demyelinating disease. Nitric Oxide. 2009;22:197–204
  142. Yao SY, Rose A, Chandramohan N, Whetsell W, Sriram S. In vitro and in vivo induction and activation of nNOS by LPS in oligodendrocytes. J. Neuroimmunol. 2010;145–156
  143. Zeis T, Graumann U, Reynolds R, Schaeren-Wiemers N. Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain. 2008;131:288–303

PII: S0165-5728(11)00229-3

doi: 10.1016/j.jneuroim.2011.08.012

Journal of Neuroimmunology
Volume 239, Issue 1 , Pages 13-20 , 28 October 2011

Article Tools

* Image Usage & Resolution